Free Trial

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech logo
$110.51 -0.49 (-0.44%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
14

Based on 18 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$137.91
24.88% Upside
According to the 18 analysts' twelve-month price targets for BioNTech, the average price target is $137.91. The highest price target for BNTX is $171.44, while the lowest price target for BNTX is $110.00. The average price target represents a forecasted upside of 24.88% from the current price of $110.44.
Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

Sign Up

BNTX Analyst Ratings Over Time

TypeCurrent Forecast
7/15/24 to 7/15/25
1 Month Ago
6/15/24 to 6/15/25
3 Months Ago
4/16/24 to 4/16/25
1 Year Ago
7/16/23 to 7/15/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
3 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$137.91$138.25$143.44$111.70
Forecasted Upside24.88% Upside29.72% Upside45.99% Upside32.58% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.80
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside24.25% Upside8,718.13% Upside10.67% Upside
News Sentiment Rating
Positive News

See Recent BNTX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetOverweight ➝ Overweight$132.00 ➝ $133.00+18.45%
6/25/2025HC Wainwright
1 of 5 stars
Robert Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$138.00+31.32%
6/3/2025Truist Financial
3 of 5 stars
Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00+33.39%
6/2/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$112.00+2.47%
5/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Neutral$110.00+12.79%
5/22/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$120.00 ➝ $116.00+17.24%
5/6/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $140.00+38.48%
3/11/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$171.44 ➝ $171.44+65.58%
3/11/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Etzer Darout
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$130.00 ➝ $143.00+35.74%
12/11/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$170.00+45.49%
11/19/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$130.00+27.61%
11/19/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$110.00 ➝ $125.00+22.71%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$132.00 ➝ $122.00+10.28%
10/7/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$97.00 ➝ $136.00+10.88%
9/19/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$95.00 ➝ $150.00+33.87%
9/18/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$97.00 ➝ $131.00+5.04%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$96.00 ➝ $150.00+21.49%
9/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$125.00 ➝ $150.00+23.75%
8/2/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:56 PM ET.


Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 9, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BioNTech SE:

  • The current stock price is around $102, which is significantly lower than its 52-week high, indicating potential for growth.
  • BioNTech SE has a strong financial position, with a quick ratio of 10.02 and a current ratio of 10.18, suggesting excellent liquidity and ability to meet short-term obligations.
  • The company has a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt for financing, which can be attractive to risk-averse investors.
  • Recent institutional interest has increased, with several hedge funds and institutional investors modifying their holdings, which can signal confidence in the company's future performance.
  • BioNTech SE is actively involved in developing immunotherapies for cancer and infectious diseases, positioning itself in a growing and essential sector of biotechnology.

BioNTech
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The company has a negative P/E ratio of -31.74, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Trading volumes have been lower than average, which may indicate reduced investor interest or liquidity issues in the stock.
  • Despite a strong market cap of approximately $25.94 billion, the stock has experienced significant volatility, which can pose risks for investors looking for stability.
  • Recent fluctuations in stock price may reflect uncertainty in the biotechnology sector, particularly regarding regulatory approvals and market competition.
  • Institutional ownership stands at 15.52%, which, while significant, may suggest that the majority of shares are held by retail investors, potentially leading to higher volatility.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $137.91, with a high forecast of $171.44 and a low forecast of $110.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 24.88% based on their 12-month stock forecasts.

BioNTech has been rated by research analysts at Citigroup, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, The Goldman Sachs Group, and Truist Financial in the past 90 days.

Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.83 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BNTX compares to other companies.


This page (NASDAQ:BNTX) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners